CytRx Corp. buy melinda
Start price
19.05.17
/
50%
€2.73
Target price
25.05.17
€4.33
Performance (%)
23.59%
End price
25.05.17
€3.38
Summary
This prediction ended on 25.05.17 with a price of €3.38. The prediction had a final performance of 23.59%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| CytRx Corp. | - | - | - | - |
| iShares Core DAX® | -1.553% | -0.123% | 12.654% | 57.846% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.546% | 93.736% |
| iShares Nikkei 225® | 1.640% | 5.468% | 17.939% | 51.788% |
| iShares S&P 500 | 0.114% | -0.217% | 1.586% | 61.648% |
Comments by melinda for this prediction
In the thread CytRx Corp. diskutieren
Gesundheit | Biotechnologie | Vereinigte Staaten
Die Registrierung für Phase 2 abgeschlossen ist . Diskussion des Poster auf der ASCO am 3. Juni 2017. Phase - 3 - Test für das dritte Quartal 2017 geplant.